Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Abcellera Biologics Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active matter represents the current focus of the company's patent prosecution. The examination of this portfolio is conducted by 1 distinct examiner and is situated within 1 distinct art unit, reflecting a focused technical scope for the pending application.
The examiner assigned to this case is BAILEY, STEVEN WILLIAM, who is listed as the busiest examiner with 1 pending office action. Because the 1 pending office action is the only one currently active, BAILEY, STEVEN WILLIAM is responsible for the company's pending review. This concentration means the prosecution outcome is directly tied to the interactions with this specific examiner.
For the practitioner, working within 1 distinct art unit allows for a specialized focus on the relevant biotechnology standards. However, the lack of other pending matters means there are no alternative examiners to provide different perspectives on the portfolio. Success depends on navigating the specific requirements and feedback provided by BAILEY, STEVEN WILLIAM within the 1 distinct art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAILEY, STEVEN WILLIAM | 1 | 31.6% | +15.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17860760 | Antibody Competition Model Using Hidden Variable Affinities | BAILEY, STEVEN WILLIAM | 11d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17860760 | Antibody Competition Model Using Hidden Variable Affinities | BAILEY, STEVEN WILLIAM | 11d overdue |
| Art Unit | Apps |
|---|---|
| 1687 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17860760 | Antibody Competition Model Using Hidden Variable Affinities | BAILEY, STEVEN WILLIAM | 1687 | §101§103§112 | Final Rejection | 11d overdue | Pending | Jul 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial